Product logins

Find logins to all Clarivate products below.


Multiple Sclerosis – Geographic Focus: China – Multiple Sclerosis: China In-Depth (China)

Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in that country. Traditionally, MS patients in China have been treated with disease-modifying therapies (DMTs) (IFN-β-1b [Bayer’s Betaferon], teriflunomide [Sanofi’s Aubagio], fingolimod [Novartis’s Gilenya], and siponimod [Novartis’s Mayzent]) and immunosuppressants (such as methotrexate, mitoxantrone, rituximab, azathioprine). In addition, the approval of ofatumumab (Novartis’s Kesimpta) and dimethyl fumarate (Biogen’s Tecfidera) in 2021 will boost the use of novel agents for the treatment of MS in China, thus increasing overall market sales. Despite the launch and availability of multiple DMTs in this market, pricing and reimbursement dynamics will continue to play a critical role in determining how the treatment paradigm will evolve over the next 10 years. Understanding these intersecting factors will be key to the success of current and future players in this market.

QUESTIONS ANSWERED

  • What is the diagnosed prevalence of different clinical forms of MS, and how are these patients treated today? Do treatment management strategies differ between urban and rural China?
  • Which are the most commercially relevant drugs in this market and why?
  • What are interviewed experts’ insights into current treatment options?
  • What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
  • What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

March 2023

Geography

China

Primary research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists.

Epidemiology

Diagnosed prevalence of MS (CIS, RR-MS, SP-MS, and PP-MS) in China, segmented by urban vs. rural; clinically relevant and market-relevant drug-treatable populations.

Forecast

10-year, annualized, drug-level sales and patient share of key MS therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.

Emerging therapies

Phase III/PR: 5 drugs; Phase II: 4 drugs; Phase I: 3 drugs.

Related Market Assessment Reports

Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…